THERAMEX
20.3.2023 17:29:26 CET | Business Wire | Press release
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures.
Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil.
“Theramex has again shown its commitment to women and the care and good management of bone health, by adding this important product to our Osteoporosis franchise. We are delighted to be entering into this partnership with Radius, building on our expanding portfolio and aligning missions to reduce fracture risks for many postmenopausal women suffering from osteoporosis.” - Rob Stewart, CEO of Theramex
“We are thrilled to have Theramex bring abaloparatide to postmenopausal women in Europe who could benefit from this impactful treatment. Our aligned, strategic vision of bringing effective solutions to the right patient gives us unwavering confidence in this partnership. We look forward to seeing the continued global expansion of abaloparatide to patients with osteoporosis worldwide.” - Scott Briggs, CEO of Radius
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause, and osteoporosis. Theramex’s commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.
www.theramex.com
About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 for the treatment of men with osteoporosis at high risk for fracture.
ELADYNOS®(abaloparatide) injection was approved by the European Medicines Agency for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapies. This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines.
www.radiuspharm.com
FOR MEDIA AND INVESTORS ONLY
ELAD_HQ_PRESSR_009443 D.O.P 8/3/23
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005585/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs to Acquire U.S. Rare Earth and Critical Minerals Company Powering Defense and National Security14.5.2026 14:01:00 CEST | Press release
Proposed Acquisition Would Position Mobix Labs Inside Strategic U.S. Supply Chains Powering Defense, National Security, and AI Infrastructure Mobix Labs, Inc. (Nasdaq: MOBX) today announced it has signed a non-binding Letter of Intent to acquire Special Project Delivery LLC ("SPD"), a strategic infrastructure platform building sovereign U.S. supply chains for rare earth elements, critical minerals, and energy storage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514342224/en/ U.S.A F-35 Lightning II The proposed acquisition would expand Mobix Labs — already a supplier to advanced U.S. and allied defense and aerospace systems — directly into one of the world's most strategically important industrial sectors. Key Facts at a Glance~418 kilogramsof rare earth materials are estimated to be used in each F-35 Lightning II. ~4,500 kilogramsof rare earth materials are estimated to be used in each Virginia-class nuclear submarine
Enterprise AI Hits the Wall: NTT DATA Research Reveals Growing Privacy and Sovereignty Barriers14.5.2026 14:00:00 CEST | Press release
Demands for privacy and sovereignty expose limits of architectures built for centralized and borderless data flows. Data jurisdiction has become a core design parameter, shifting away from globally integrated systems to regionally bounded architectures. Organizations that redesign early are gaining a measurable edge in AI readiness and scale. NTT DATA, a global leader in AI, digital business and technology services, today released new research showing that enterprise AI is outgrowing the architecture and infrastructure beneath it as data privacy and sovereignty requirements tighten. The research finds a widening split between enterprises that are redesigning AI for control, locality and security, and organizations still layering AI into environments that were not built to support these requirements. For years, enterprise architecture moved data across systems, clouds, applications and borders with increasing speed and efficiency. AI is exposing the limits of that model. Sensitive data
Mary Kay Launches Global Social Squad Program to Empower the Next Generation of Digital Beauty Leaders14.5.2026 14:00:00 CEST | Press release
A Global Program Connecting 70+ Emerging Creators Among Independent Beauty Consultants with Digital Education, Mentorship, And Real‑World Beauty Brand Experience. Mary Kay Inc., a global leader in beauty and entrepreneurship, announces the launch of its Global Social Squad (GSS) Pilot Program – a groundbreaking initiative designed to empower Mary Kay Independent Beauty Consultants (IBCs) as dynamic digital brand advocates and next-generation social media storytellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514978222/en/ The Global Social Squad ignites a diverse and talented group of 73 Mary Kay Independent Beauty Consultants with representation across 15 markets in four regions: North America, Asia Pacific, Latin America, and Europe. These digital leaders create engaging, high-quality content, participate in global campaign activations, and share practical social media strategies with their communities and other I
Vista Equity Partners Establishes Abu Dhabi Office14.5.2026 14:00:00 CEST | Press release
Securing Full Regulatory Authorization from ADGM deepens Vista’s commitment to the Middle East and expands the firm’s global platform for enterprise software investing Vista Equity Partners (“Vista”), a global technology investor that specializes in enterprise software, today announced the opening of its new office in Abu Dhabi within ADGM, the city’s international financial center. VEPM Middle East Limited has received full authorization from ADGM’s Financial Services Regulatory Authority (FSRA), enabling the firm to advise on investments and arrange deals in investments across the region. The Abu Dhabi office reflects Vista’s expanded strategic presence in the Middle East and the region’s increasingly central role in global technology investment and innovation. Established in 2013, ADGM has emerged as one of the world’s leading financial centers, connecting global investors with regional opportunities. Vista joins a growing community of leading global investment firms that have estab
Eighteen48 Partners Announces First Close of Eighteen48 Private Equity Fund I at €175 million14.5.2026 13:56:00 CEST | Press release
Eighteen48 Partners today announced the first close of Eighteen48 Private Equity Fund I (the “Fund”) at €175 million. The Fund, which is targeting €350 million, is focused on European middle-market buyout transactions sourced through Independent Sponsors. Since 2020 Eighteen48 Partners have deployed more than €200 million into this strategy, which aims to provide investors with diversified exposure to off-market sourced transactions. The first close was supported by significant re-up commitments from Eighteen48 clients as well as commitments from institutions, family offices and UHNWs, underscoring the strength of the firm’s platform, track record and experience as well as growing momentum in the Independent Sponsor space. Julien Sevaux, Founding Partner and CEO, commented: “We are increasingly excited by the opportunity in the growing independent sponsor segment of European private equity - a corner of the market we believe remains largely overlooked by investors yet offers compelling
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom